SeraCare Expands Cellular Line with Addition of Cryopreserved CD8+ T-cells and CD19+ B-cells

SeraCare Life Sciences, announces today the expansion of its cellular product line with the addition of Cryo-T8 Human CD8+ T-cells and Cryo-B Human CD19+ B-cells to its AccuCell® Peripheral Blood Mononuclear Cell (PBMC) portfolio.

Cryopreserved primary cells are particularly valuable for use in the study of autoimmune disease, inflammatory disease, oncology and infectious disease. SeraCare’s rigorously optimized and validated processes allow investigators to access cryopreserved primary cells with greater than 90% viability and purity.

“The availability of large lots from the same donor provides a significant advantage for investigators, especially those performing longitudinal studies, as it greatly reduces study variability and facilitates consistency and reproducibility,” said Tina Patel, Associate Technical Product Manager, SeraCare Life Sciences. “SeraCare’s extensive sourcing network and donor program also enables the company to potentially contact the same donors for additional draws.”

The readily available, off-the-shelf Cryo-T8 and Cryo-B Human PBMC subsets include a broad range of donor demographics and related HLA information. In addition, SeraCare can provide cryopreserved cells customized to individual customer needs including disease-specific, allergen-specific and genotype-specific options. PBMC and subsets are available in custom fill sizes and cell numbers, and a variety of cell-based assays and functional testing services are offered by SeraCare for customized research needs.

Cryo-T8 Human CD8+ T-cells and Cryo-B Human CD19+ B-cells are the fifth and sixth cellular types launched in the SeraCare AccuCell® PBMC portfolio, respectively. According to Patel, SeraCare had added Cryo-M Human Monocytes and Cryo-T4 Human CD4+ T-cells just in the last few months and the company plans to continue expanding its cellular product portfolio.